Literature DB >> 6807080

In vitro detection of mild inhibitors to factor VIII in hemophilia.

N P Ewing, C K Kasper.   

Abstract

Plasma samples from patients with severe classic hemophilia, suspected of having mild inhibitors not detected in the standard Bethesda inhibitor test, were examined in modified Bethesda tests and in a screening test based on the activated partial thromboplastin time (APTT). The APTT test was more sensitive to mild inhibitors than any modification of the Bethesda method. Increasing the ratio of patient to normal plasma in either the APTT or the Bethesda test improved the sensitivity to mild inhibitors. If a patient's plasma is used as its own control in the APTT test, results are more consistent as minor fluctuations in the APTT occur over time.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6807080     DOI: 10.1093/ajcp/77.6.749

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  4 in total

1.  Severe bleeding in a patient with spontaneous factor VIII inhibitor and acute exacerbation of chronic pancreatitis.

Authors:  C Martínez; J Mateo; M Pérez; J Errando; E Quintana; J Fontcuberta
Journal:  Intensive Care Med       Date:  1996-11       Impact factor: 17.440

2.  Acquired factor VIII inhibitor preceding chronic lymphocytic leukemia.

Authors:  J Mateo; R Martino; M Borrell; M Garí; F Casas; J Fontcuberta
Journal:  Ann Hematol       Date:  1993-12       Impact factor: 3.673

3.  Hemophilia care in India: a review and experience from a tertiary care centre in uttar pradesh.

Authors:  Shubha Phadke
Journal:  Indian J Hematol Blood Transfus       Date:  2011-07-12       Impact factor: 0.900

4.  Rare but not Abdicated: Status of Haemophilia in foothills of Himalaya, Uttarakhand: A cross-sectional study.

Authors:  Vyas K Rathaur; N K V Vigneshwar; Ayesha Imran; Monika Pathania; Sonam Agrawal; Swathi Chacham; Prashant K Verma; Nowneet K Bhat
Journal:  J Family Med Prim Care       Date:  2021-04-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.